Warfarin is a mainstay atrial ibrillation (AF) treatment, yet it has a narrow therapeutic window. Novel agents have been successfully tested against warfarin, yet no direct comparison among them is available. We thus performed a pair-wise and warfarin-adjusted network metaanalyses of novel oral anticoagulants for AF.
PICKING THE BEST NOVEL ORAL ANTICOAGULANT FOR ATRIAL FIBRILLATION: EVIDENCE FROM A WARFARIN-CONTROLLED NETWORK META-ANALYSIS / Roversi, S; Malavasi, Vincenzo; D'Ascenzo, F; Abbate, A; Castagno, D; Van Tassell, B; Casali, Edoardo; Modena, Mg. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN 0735-1097. - 59:13(2012), pp. E598-E598. (Intervento presentato al convegno Congress of American College of Cardiology tenutosi a Chicago, IL nel 24-27 MARCH 2012) [10.1016/s0735-1097(12)60599-3].
PICKING THE BEST NOVEL ORAL ANTICOAGULANT FOR ATRIAL FIBRILLATION: EVIDENCE FROM A WARFARIN-CONTROLLED NETWORK META-ANALYSIS
MALAVASI, VINCENZO;CASALI, EDOARDO;Modena, MG
2012
Abstract
Warfarin is a mainstay atrial ibrillation (AF) treatment, yet it has a narrow therapeutic window. Novel agents have been successfully tested against warfarin, yet no direct comparison among them is available. We thus performed a pair-wise and warfarin-adjusted network metaanalyses of novel oral anticoagulants for AF.
| File | Dimensione | Formato | |
|---|---|---|---|
|
PICKING_THE_BEST_NOVEL_ORAL_ANTICOAGULAN.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
122.76 kB
Formato
Adobe PDF
|
122.76 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
